Pages that link to "Q35587175"
Jump to navigation
Jump to search
The following pages link to Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? (Q35587175):
Displaying 13 items.
- Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? (Q24804259) (← links)
- Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study (Q24813954) (← links)
- Diagnosis and management of the metabolic syndrome in obesity (Q28192856) (← links)
- Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins (Q28200554) (← links)
- Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease (Q28217889) (← links)
- Metabolic syndrome, inflammation and atherosclerosis (Q28219348) (← links)
- Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments. (Q36093161) (← links)
- Pharmacogenomics of cholesterol-lowering therapy (Q36335716) (← links)
- Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus (Q36702091) (← links)
- Diabetic dyslipidemia: extending the target beyond LDL cholesterol (Q37757979) (← links)
- Nigella sativa Relieves the Altered Insulin Receptor Signaling in Streptozotocin-Induced Diabetic Rats Fed with a High-Fat Diet. (Q41694546) (← links)
- Normalization of metabolic syndrome using fenofibrate, metformin or their combination (Q46959415) (← links)
- Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome (Q96129205) (← links)